Ketoprofen
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Ketoprofen
- Ketoprofen: From Rheumatoid Arthritis and Osteoarthritis to Acromesomelic Dysplasia, Hunter-Thompson Type
Ketoprofen: From Rheumatoid Arthritis and Osteoarthritis to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) originally used for rheumatoid arthritis, osteoarthritis and other arthropathies. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, but there are currently 0 clinical trials and 0 publications supporting this direction. This prediction is model-only and should be treated as a computational signal, not an evidence-based indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, osteoarthritis, arthropathy (from the knowledge graph; no approved indication text is available in the Singapore licence records) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ketoprofen is a non-selective cyclooxygenase (COX) inhibitor of the NSAID class. It provides symptomatic anti-inflammatory and pain relief in joint disease.
Acromesomelic dysplasia, Hunter-Thompson type is a rare skeletal dysplasia caused by loss-of-function mutations in CDMP1/GDF5, which disrupt BMP/GDF signalling. A COX inhibitor is not expected to correct this genetic defect. The high TxGNN score most likely reflects proximity in the knowledge graph through shared skeletal or joint phenotypes, not a pharmacological rationale. At most, ketoprofen could offer symptomatic pain relief for secondary joint problems, which would be ordinary analgesic care rather than repurposing.
Other predicted indications. Among the top 10 predictions, two are more biologically plausible than the rest:
- Spondyloarthropathy, susceptibility to (score 99.86%): NSAIDs are first-line therapy for spondyloarthritis, and ketoprofen's existing arthropathy and rheumatoid arthritis indications overlap. This is the most plausible candidate. No ketoprofen-specific trials or literature were in the data compiled for this report, so it remains L5. Targeted literature retrieval could likely raise the level, because class-level NSAID evidence exists.
- Juvenile arthritis due to defect in LACC1 (score 99.74%): NSAIDs are commonly used for symptom control in juvenile arthritis. This gives a symptomatic rationale but not disease modification, and paediatric safety and dosing would need separate evaluation.
The remaining predictions are rare genetic or developmental conditions (e.g., brachyolmia, pseudoachondroplasia, WHIM syndrome, myosclerosis). There is no supporting mechanism or evidence for them.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
All 10 registrations are valid single-ingredient products. Approved indication text is not available in the records compiled for this report. The five listed here are representative of the main dosage forms.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| SIN15748P | KETOFEN GEL 2.5% w/w | Gel | Hovid Bhd |
| SIN06755P | FASTUM GEL 2.5% | Gel | A. Menarini Manufacturing Logistics and Services S.R.L. |
| SIN12153P | PRONALGES 100 TABLET 100 mg | Enteric coated tablet | PT Dexa Medica |
| SIN15832P | KETOTOP PAIN RELIEF PLASTER 30MG | Plaster | Handok Inc |
| SIN10768P | KEFENTECH PLASTER 30 mg/sheet | Plaster | Jeil Health Science |
Available forms span topical (gel), plaster and oral (enteric coated tablet) routes.
Safety Considerations
- Contraindication-related conditions (knowledge graph, not label text): hypertension/hypertensive disorder, liver failure, kidney disease, peptic ulcer disease (including active), blood coagulation disease, myocardial infarction, coronary thrombosis, cardiovascular and heart disease, hemoglobinopathy, pyoureter.
- Drug Interactions: 100 interactions were identified in total. The sample reviewed includes:
- Moderate: acetylsalicylic acid, corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), metformin, glimepiride, chlorpropamide, mesalazine, balsalazide, naltrexone, potassium citrate, potassium bicarbonate, picosulfuric acid, polyethylene glycol (3350 with electrolytes)
- Minor: famotidine, ranitidine, cimetidine, linaclotide
Please refer to the package insert for the approved warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on the model score. There are no clinical trials or publications, and no plausible mechanism links COX inhibition to correcting the GDF5-related genetic defect. The evidence level is L5. Ketoprofen's cardiovascular, renal, hepatic and gastrointestinal risk profile also argues against pursuing this indication without supporting data.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website, to allow safety screening
- Mechanism of action data for ketoprofen (e.g., from DrugBank)
- Targeted literature and trial searches, prioritising spondyloarthropathy and LACC1-related juvenile arthritis, which have more plausible NSAID-based rationales and may qualify as research questions
- For any paediatric or rare-disease use, a separate assessment of dosing and safety, and of route compatibility with the available gel, plaster and oral forms
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.